<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute myeloid leukemia (AML): Management in medically-unfit patients</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute myeloid leukemia (AML): Management in medically-unfit patients</h1>
<div class="graphic"><div class="figure"><div class="ttl">Acute myeloid leukemia (AML): Management in medically-unfit patients</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">Medically-unfit generally refers to patients with impaired PS (eg, ECOG PS 3) and moderate comorbidities (eg, CCI 3), rather than age, per se. This algorithm should be used together with related UpToDate topics for evaluation and diagnosis of AML, assessment of medical fitness, and management of AML.</div><div class="graphic_footnotes"><p>AML: acute myeloid leukemia; 
        CCI: Charlson cormorbidity index; 
        ECOG: Eastern Cooperative Oncology Group; 
        PS: performance status; 
        HMA: hypomethylating agent; 
        IDH1: isocitrate dehydrogenase 1; 
        LoDAC: low-dose cytarabine.</p>
<p>* HMAs should be used with caution in patients with severe kidney or liver disease, as such patients were excluded from clinical trials; HMA dose should be reduced or delayed for unexplained declines in kidney or liver function. </p>
<p>¶ LoDAC-based combinations are preferred, rather than single-agent cytarabine. Examples include LoDAC plus venetoclax, LoDAC plus glasdegib, or LoDAC plus clofarabine.</p>

    Δ Selected patients may be candidates for targeted agents based on molecular findings and/or blast immunophenotype; examples include IDH1/2 inhibitors, gilteritinib, or gemtuzumab ozogamicin.</div><div id="graphicVersion">Graphic 139975 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
